To create a global platform in which there are infinite possibilities and zero limitations on what you can accomplish in biotechnology.
What is BIOHK2022?
An international convention organized by HKBIO to introduce novel state-of-the-art biotech innovations from around the globe, with the purpose of providing an extensive platform to allow pioneers of the biotech industry to convene. From infectious diseases like COVID-19, to the latest cancer treatments and diagnostics to big data analytics, BIOHK2022 is an unparalleled event covering the most relevant and timely topics in biotechnology BIOHK2022 comprises of three parts:
Exhibition – SHOWCASE and CONNECT
- Showcase your product to the world whilst simultaneously learning about other leading innovations
Conference and Pitch Sessions – SHARE AND INSPIRE
- Take part in invaluable discussions about the latest topics and industry trends in biotech
One2One Partnering – PROMOTE AND ESTABLISH
- Promote your company and connect with prospective partners in the biotech market, succeed in forming new collaborations and building your international network
On the last part of the convention, the convention will be open to the public and visitors will be able to participate in public talks. Use this opportunity to promote your company brand, market testing products, and ideas to the end users!
Register now and see you at BIOHK2022!
Hong Kong Biotechnology Organization (HKBIO) established in 2010 by reputable industry and esteemed academic representatives, HKBIO is a non-profit organization which continuously strives to promote Hong Kong as the biotech hub of Asia. HKBIO has organized and sponsored several successful events in the past that highlighted the substantial potential of Hong Kong’s Biotechnology sector.
The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix aspires to foster and create business opportunities, supply and nurture leaders for the community, and network and share information and experience among its members.
Ausvic Capital is a global biotech, artificial intelligence (AI) and cloud computing-focused investment group founded by leading investors in 2018. The team has extensive experience in venture capital investing and business management, with an impressive track record behind their name. Leveraging on its extensive network around the world, Ausvic focuses on the most novel life science and AI-related companies and technologies in the United States, Europe, and China.
The Asian Fund for Cancer Research Limited (AFCR) is committed to fund cancer research, especially those cancers prevalent in Asian populations, and promote global collaborations for high impact to save the lives of cancer patients.
Guangdong-Hong Kong-Macao Greater Bay Area Alliance, corralling the two Special Administrative Regions (SARs) of Hong Kong and Macao with Guangdong, one of the richest province of China’s 34 provinces. Greater Bay Area seems to possess the same core components as “the original” Bay Area: High-tech IT sectors, electronics hardware capabilities, riotous VC activity, vibrant academic and basic science research, favorable government policy, and a huge market.
Guangdong Medical Valley (GDMV), established in 2014, specializing in medical instrument and bio-pharmaceutical industry, is an all-round investment incubation platform, including the medical equity investment and medical industry supporting service. It is the one of the founders of China Medical Industry Alliance and the standing council unit of Guangdong Medical Device Management Association.
The National Foundation for Cancer Research (NFCR) is a non-profit organization that provides scientists in the lab the funding they need to make and apply game-changing discoveries in cancer treatments, detection, prevention and, ultimately, a cure. It has distinguished itself in the cancer sector by emphasizing long-term, transformative research often overlooked by other major funding sources. With the help of more than 5.3 million individual donors over the last 46 years, NFCR has delivered more than $380 million in funding to public education and cancer research leading to several important, life-saving discoveries.